Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Enzalutamide in Biochemically Recurrent Prostate Cancer
The trial showed that enzalutamide plus leuprolide significantly improved overall survival compared to leuprolide alone in patients with high-risk biochemically recurrent prostate
New Reference: Revumenib for Rel/Ref KMT2A-Rearranged AML
The AUGMENT-101 study showed that revumenib led to high response rates in relapsed or refractory KMT2A-rearranged acute leukemia. Patients had an overall response rate of 63.2% wit
New Reference: Belantamab for Multiple Myeloma
BVd therapy significantly prolonged progression-free survival compared to DVd in patients with relapsed or refractory multiple myeloma. It was associated with a higher rate of comp
New Indication: Revumenib for Rel/Ref NPM1-Mutated AML
In this study, revumenib exhibited a promising overall response rate of 46.9% in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The median overall surviv
New Drug: Zanzalintinib for Metastatic Colorectal Cancer
In the STELLAR-303 trial, zanzalintinib combined with atezolizumab showed significant improvements in overall survival compared to regorafenib in patients with previously treated m
New Indication: Quizartinib for Newly Diagnosed AML (FLT3-ITD Negative)
The QUIWI study demonstrated that quizartinib, when added to standard chemotherapy, significantly prolonged both event-free and overall survival in patients with newly diagnosed FL
New Reference: Rituximab – Ibrutinib for Untreated Mantle Cell Lymphoma
The ENRICH trial showed that the combination of ibrutinib and rituximab significantly improved progression-free survival compared to standard immunochemotherapy in older patients w
New Reference: Neoadjuvant FOLFIRINOX vs. Chemoradiation for Pancreatic Cancer
The phase 3 PREOPANC-2 trial found no significant difference in median overall or progression-free survival between neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy i
New Indication: Lenvatinib + Pembrolizumab for Thymic Carcinoma
The PECATI trial demonstrated promising activity of lenvatinib plus pembrolizumab in patients with pretreated metastatic B3 thymoma and thymic carcinoma, achieving a progression-fr
